Abstract
AbstractClopidogrel bisulfate 1 is an antiplatelet agent used for the treatment of platelet aggregation to prevent blood clotting. During the laboratory process development of clopidogrel 1, we have identified six potential related substances (6, 7, 8, 9, 10 and 11) which are formed at various stages of the preparation of 1. Out of these, three related substances (6, 7 and 11) are found to be unprecedented. The present work details the synthesis of these related substances by employing efficient synthetic strategies. The present work also describes the pathways for the formation of these substances and their control strategies during clopidogrel manufacturing.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
